National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
about
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Comparing Prognostic Tools for Cancer Screening: Considerations for Clinical Practice and Performance Assessment.Lethal Prostate Cancer in the PLCO Cancer Screening Trial.Prostate Cancer Screening: A Brief Tool to Incorporate Patient Preferences in a Clinical Encounter.Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.The Effect of Electronic Health Record Use and Patient-Centered Communication on Cancer Screening Behavior: An Analysis of the Health Information National Trends Survey.Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening.Contemporary management of men with high-risk localized prostate cancer in the United States.The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer.Revisiting Prostate Cancer Screening Practices Among Vermont Primary Care Physicians.What's new in screening in 2015?Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.Is prostate cancer stage migration continuing for black men in the PSA era?Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions.Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.Implications of prostate-specific antigen screening guidelines on clinical practice at a Canadian regional community hospitalCommentary: Building an Evidence Base for Promoting Informed Prostate Cancer Screening Decisions: An Overview of a Cancer Prevention and Control Program.US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.Prostate cancer in black men: Is it time for personalized screening approaches?Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.A Content Analysis of YouTube™ Videos Related to Prostate Cancer.Prostate-specific antigen screening: An update of physician beliefs and practices.Summary statement on screening for prostate cancer in Europe.Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7.Prostate cancer screening: Do guidelines matter?The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.Prostate cancer screening in Europe and Asia.Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States.Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.Cost implications of PSA screening differ by age.Prevalence of and factors associated with mammography and prostate-specific antigen screening among World Trade Center Health Registry enrollees, 2015–2016.Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic reviewChanges in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening
P2860
Q30239973-7171B3E7-474F-4B26-B1E5-8A0329172A33Q30746254-C1E97FBF-22CD-4D53-8D4A-B002FD3702BFQ36940678-960022C6-E580-4231-AD6C-1920A7DB8551Q37008842-F06DA6F9-B93E-45FF-945D-9D3AE6E3C3E1Q37393072-4DB19D3E-2FC0-45F2-89DA-97277E7E8FC3Q37716322-84D230A4-FB4E-4B4E-B3EC-CC3DB6BD0009Q38662099-56578187-E73A-42CB-8221-521AC02222CEQ38668005-073C7FA9-732F-4036-9FFE-07C68BA15D47Q38717765-34025CCF-B5DD-46DC-84B5-ECABDCE23CF0Q38721090-BAC46BF4-E349-4D5D-9646-664F49774FABQ38723029-2070A19F-BAC8-4438-9193-E871C4AEAE73Q38871819-B8E910AC-1F05-4829-ACE0-5954DCA9149EQ39356227-ADADF73C-FB03-4DE8-A458-55763FD11DE5Q39362101-52ED74E9-5662-41A1-92DB-4E7628E7E345Q39639104-0FB58D44-C088-4686-BECA-A4A0EAD4AA80Q40254848-97B9CF0F-45AF-46F8-A2D5-C812F4ED78D7Q40377882-4D6F40CB-0480-47A9-8EFD-1F0066847FA8Q40650299-D05377BE-D0F9-4B76-A005-7B617AC7FE8BQ40852349-6C68BDDA-B3AD-475C-BC3E-649A7E6ED0CEQ41032260-E8BF8FCE-8556-41EC-BD45-EAFF0E18C58AQ41240464-4E0104DB-9BB4-46E4-95F3-D1AD8CFD6930Q42329698-D66EEAE6-5D8A-4961-A39D-6004EE8C58EEQ44449601-A32E2670-F726-4C36-BB5F-11C3F21BF546Q46008421-5D444F88-9656-4DA4-9DA1-BF15365D45B6Q46519121-DD337141-AB17-409A-847C-0EDCA42A664CQ47102575-4DF6CA31-7B3A-4917-B9FC-4765EC2DFBDCQ47161429-636BA20A-F26C-4D11-9BE2-B8BC91AD501AQ47901606-C7BA2307-9ACD-4EA7-9FAE-775D6A706C28Q48080052-C0210C67-C99C-4EC7-A8DA-7DEB3FBB798AQ48340105-CFC4178F-95A7-4463-926F-4C58DB0E0BD9Q51320797-5AFEFC30-55DA-4029-812D-2764786D5D34Q51771288-A4F61506-E228-450A-B791-BDE406A32F24Q52660669-0FB3C0F4-5152-4D51-A096-F4DA218EE99EQ52663584-3A820E30-5D25-4788-8AFB-15FF4A3B4EEDQ53732224-D347E765-9206-4737-81BE-0A1D181C655EQ55032029-5FB704A9-0132-4B1A-BA43-406DD1DD97A0Q55424500-C5007B03-A9AF-4E8E-96D9-993AFBD1DACCQ57106309-CEB13E9F-C973-4BB1-8CAA-F33EA7EBCFBCQ58736527-C319941B-1047-4FAA-86D2-3AE56E8267E2
P2860
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
National Prostate Cancer Scree ...... cific Antigen-Based Screening.
@en
type
label
National Prostate Cancer Scree ...... cific Antigen-Based Screening.
@en
prefLabel
National Prostate Cancer Scree ...... cific Antigen-Based Screening.
@en
P2093
P356
P1476
National Prostate Cancer Scree ...... cific Antigen-Based Screening.
@en
P2093
Dezheng Huo
Michael W Drazer
Scott E Eggener
P304
P356
10.1200/JCO.2015.61.6532
P407
P577
2015-06-08T00:00:00Z